Health & Biotech
Headquartered in Auckland, New Zealand, Aroa Biosurgery is a soft-tissue regeneration company committed to unlocking regenerative healing for everybody through its patented AROA ECM™ complex wound and tissue reconstruction products.
The company was founded in 2008 by Veterinarian Surgeon Dr Brian Ward, who discovered that a tissue scaffold called the extra cellular matrix (ECM) found in the forestomach of sheep has a similar structure to human tissue and contains over 150 proteins known to be important in the healing process.
Listed on the ASX since 2020, Aroa Biosurgery has established USA operations, regulatory approval in over 50 countries and employs over 270 people in New Zealand and North America.
Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. www.aroabio.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: Who fancies 22 minutes of exercise? And ASX health stocks are up (finally)
Health & Biotech
Wound wizard Aroa forecasts 30pc annual growth as it transitions to ‘highly profitable business’
Health & Biotech
ScoPo’s Powerplays: Should have stayed in bed as ASX stocks fall but Neuren makes S&P ASX 200
Health & Biotech
ScoPo’s Powerplays: ASX health stock fall but hold onto your hat for reporting season
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as Volpara records third quarter of positive cashflow
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ScoPo’s Powerplays: ASX health stocks… could be worse
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news
Health & Biotech
ScoPo’s (actually still Iain’s) Powerplays: ASX health sector falls, but several stocks on upward run
Health & Biotech
ASX Health Stocks: Pharmaxis and Aroa lift on FDA news, Cynata to commence Phase 2 trial
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines update
News
After Neuren’s success, which other ASX health stocks are knocking on the US FDA door?
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but cap raises show money flowing into sector
News
ASX Quarterlies: Junior techs and biotechs still thriving despite difficult conditions
Experts
Innovation never sleeps: Franklin Templeton says watch these 5 big tech shifts this quarter
Health & Biotech